Pneumococcal vaccines for cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 8, 2014, Pages

  Burgess, Laura ^a   Southern, Kevin W ^b  

^a ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PNEUMOCOCCUS VACCINE;

CYSTIC FIBROSIS; DATA ANALYSIS; DRUG EFFICACY; HUMAN; MORBIDITY; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ADULT; CHILD;

ADULT; CHILD; CYSTIC FIBROSIS; HUMANS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES;

EID: 84907185242     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008865.pub3     Document Type: Review

References (35)

1. Burgess L, Southern KW. Pneumococcal vaccines for cystic fibrosis. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD008865.pub2]
2. Burns J, Emerson J, Strapp JR, Yim DL, Krzewinski J, Louden L, et al.Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clinical Infectious Diseases 1998;27(1):158-63.
3. Cates C. Visual Rx. Online NNT Calculator. www.nntonline.net/ 2003.
4. Chang CC, SIngleton RJ, Morris PS, Chang AB. Pneumococcal vaccines for children and adults with bronchiectasis. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD006316.pub3]
5. Collazo T, Magarino C, Chavez R, Suardiaz B, Gispert S, Gomez M. Frequency of delta-F508 mutation and XV2C/KM19 haplotypes in Cuban cystic fibrosis families. Human Heredity 1995;45(1):55-7.
6. Deeks JJ, Higgins JPT, Altman DG, on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2011.
7. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. European Respiratory Journal 2007;29(3):522-6.
8. Frossard PM, Girodon E, Dawson KP, Ghanem N, Plassa F, Lestringant GG, et al.Identification of cystic fibrosis mutations in the United Arab Emirates. Mutations in brief no. 133. Online. Human Mutation 1998;11(5):412-3.
9. Gee L, Abbott J, Conway S, Etherington C, Webb A. Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. Thorax 2000;55(11):946-54.
10. Giannattasio A, Squeglia V, Lo Vecchio A, Russo MT, Barbarino A, Carlomagno R, et al.Pneumococcal and influenza vaccination rates and their determinants in children with chronic medical conditions. Italian Journal of Pediatrics 2010;36(1):28.
11. Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax 2007;62(4):360-7.
12. Harboe ZB, Thomsen RW, Riis A, Valentiner-Branth P, Christensen JJ, Lambertsen L, et al.Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Medicine 2009;6(5):e1000081.
13. Health Protection Agency. Pneumococcal Disease Epidemiological Data. www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Pneumococcal/EpidemiologicalDataPneumococcal/ (accessed 9 June 2010).
14. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
15. Higgins JPT, Altman DG, on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2011.
16. Hjuler T, Wohlfahrt J, Kaltoft MS, Koch A, Biggar RJ, Melbye M. Risks of invasive pneumococcal disease in children with underlying chronic diseases. Pediatrics 2008;122(1):e26-32.
17. Høiby N. Epidemiological investigation of the respiratory tract bacteriology in patients with cystic fibrosis. Acta Pathologica et Microbiologica Scandinavica. Section B, Microbiology 1974;82(4):541-50.
18. Ispahani P, Slack RCB, Donald FE, Weston VC, Rutter N. Twenty year surveillance of invasive pneumococcal disease in Nottingham: serogroups responsible and implications for immunisation. Archives of Disease in Childhood 2004;89(8):757-62.
19. Jain M, Thomson AH. Palivizumab, pneumococcal and influenza vaccination in cystic fibrosis. Journal of the Royal Society of Medicine 2009;102(Suppl 1):S23-S28.
20. Kosorok MR, Wei WH, Farrell PM. The incidence of cystic fibrosis. Statistics in Medicine 1996;15(5):449-62.
21. Kroger AT, Atkinson WL, Marcuse EK, Pickering LK. General Recommendations on Immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports 2006;55(RR15):1-48.
22. Lahiri T, Waltz DA. Preimmunization anti-pneumococcal antibody levels are protective in a majority of patients with cystic fibrosis. Pediatrics 2001;108(4):e62.
23. Malfroot A, Adam G, Ciofu O, Doring G, Knoop C, Lang AB, et al.Immunisation in the current management of cystic fibrosis patients. Journal of Cystic Fibrosis 2005;4(2):77-87.
24. May JR, Herrick NC, Thompson D. Bacterial infection in cystic fibrosis. Archives of Disease in Childhood 1972;47(256):908-13.
25. National Health Service. Pneumococcal Vaccination. www.nhs.uk/conditions/Pneumococcal-immunisation/Pages/Introduction.aspx (accessed 21 June 2010).
26. Pletz MW, Maus U, Krug N, Welte T, Lode H. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. International Journal of Microbial Agents 2008;32(3):199-206.
27. Powers CA, Potter EM, Wessel HU, Lloyd-Still JD. Cystic fibrosis in Asian Indians. Archives of Pediatrics and Adolescent Medicine 1996;150(5):554-5.
28. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135(6):1610-8.
29. Raskin S, Pereira-Ferrari L, Reis FC, Abreu F, Marostica P, Rozov T, et al.Incidence of cystic fibrosis in five different states of Brazil as determined by screening of p.F508del, mutation at the CFTR gene in newborns and patients. Journal of Cystic Fibrosis 2008;7(1):15-22.
30. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
31. Rosenbluth DB, Wilson K, Ferkol T, Schuster DP. Lung function decline in cystic fibrosis patients and timing for lung transplantation referral. Chest 2004;126(2):412-9.
32. 1 after pulmonary exacerbation in children with cystic fibrosis. Pediatric Pulmonology 2010;45(2):127-34.
33. UK Cystic Fibrosis Trust. Cystic Fibrosis. www.cftrust.org.uk/aboutcf/whatiscf/ (accessed 25 February 2012).
34. Williams BG, Gouws E, Boschi-Pinto C, Bryce J, Dye C. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infectious Diseases 2002;2(1):25-32.
35. Yamashiro Y, Shimizu T, Oguchi S, Shioya T, Nagata S, Ohtsuka Y. The estimated incidence of cystic fibrosis in Japan. Journal of Pediatric Gastroenterology and Nutrition 1997;24(5):544-7.